(Q46657583)

24 December 2017

title

Cost-effectiveness of topiramate in migraine prevention: results from a pharmacoeconomic model of topiramate treatment (English)

1 reference

24 December 2017

1 reference

1

1 reference

24 December 2017

Peter J Neumann

3

object named as

Peter J Neumann

1 reference

24 December 2017

author name string

George Papadopoulos

2

1 reference

24 December 2017

Mark Friedman

4

1 reference

24 December 2017

Jeffrey D Miller

5

1 reference

24 December 2017

Joseph Menzin

6

1 reference

24 December 2017

publication date

1 September 2005

1 reference

24 December 2017

published in

Headache

1 reference

24 December 2017

volume

45

1 reference

24 December 2017

issue

8

1 reference

24 December 2017

page(s)

1012-1022

1 reference

24 December 2017

The International Classification of Headache Disorders: 2nd edition

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2005.05182.X

Burden of migraine in the United States: disability and economic costs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2005.05182.X

Migraine--current understanding and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2005.05182.X

Pharmacologic management of acute attacks of migraine and prevention of migraine headache

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2005.05182.X

Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2005.05182.X

Topiramate for migraine prevention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2005.05182.X

Topiramate in migraine prophylaxis--results from a placebo-controlled trial with propranolol as an active control

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2005.05182.X

Topiramate in migraine prevention: results of a large controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2005.05182.X

Migraine preventive medication reduces resource utilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2005.05182.X

The estimation of a preference-based measure of health from the SF-36.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2005.05182.X

Treatment of migraine in Canada with naratriptan: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2005.05182.X

Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2005.05182.X

Economic and social impact of migraine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2005.05182.X

Migraine and reduced work performance: a population-based diary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2005.05182.X

Measuring the functional status and well-being of patients with migraine headache.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2005.05182.X

Deriving a preference-based single index from the UK SF-36 Health Survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2005.05182.X

The Migraine ACE Model: Evaluating the Impact on Time Lost and Medical Resource Use

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2005.05182.X

10.1111/J.1526-4610.2005.05182.X

21 January 2018

Identifiers

DOI

1 reference

24 December 2017

1 reference

24 December 2017